Novartis wins two prestigious Prix Galien Foundation Awards
Novartis has been awarded the prestigious 2016 Prix Galien USA Award for Best Biotechnology Product for Cosentyx® (secukinumab), as well as the Prix Galien Foundation "Discovery of the Decade" Award for Best Pharmaceutical Product for the drug Gleevec® (imatinib mesylate). The awards were presented at a ceremony in New York City. (Source: World Pharma News)
Source: World Pharma News - October 31, 2016 Category: Pharmaceuticals Tags: Featured Novartis Business and Industry Source Type: news
Long-Term Follow-Up Shows Imatinib Discontinuation Remains Safe
The STIM1 study shows that patients with chronic myeloid leukemia who have undetectable minimal residual disease can safely discontinue imatinib therapy. (Source: CancerNetwork)
Source: CancerNetwork - October 4, 2016 Category: Cancer & Oncology Authors: Dave Levitan Tags: Chronic Myeloid Leukemia Hematologic Malignancies News Source Type: news
Discovery offers prospect of shorter treatment and cure for chronic myelogenous leukemia
(Dana-Farber Cancer Institute) Although targeted drugs like Gleevec have revolutionized the treatment of chronic myelogenous leukemia, patients generally must take them for the rest of their lives and may cease benefiting from them over time. In new research that could suggest a road to cure, scientists have found that CML stem cells die in response to inhibition of a protein called Ezh2. Drugs that target the protein are currently being tested in clinical trials for other cancers. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 14, 2016 Category: Cancer & Oncology Source Type: news
A new method cuts the cost of drug-building chemicals
EPFL (École polytechnique fédérale de Lausanne) scientists design a new method to cheaply produce some of the most important chemical compounds in the pharmaceutical industry - the amines. The amines are one of the most important classes of chemical compounds today. Amines that contain a ring-like structure - called an "aryl" group - are used widely in pharmaceuticals, such as the top-selling drugs Abilify, Crestor, Gleevec, and Lidoderm. (Source: World Pharma News)
Source: World Pharma News - August 12, 2016 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
Two Generic Versions of Imatinib Launched -- but Will Prices Drop? Two Generic Versions of Imatinib Launched -- but Will Prices Drop?
Two new generic versions have now been launched and will be vying with Novartis and Sun Pharmaceuticals for market share, but the question remains: will it even affect the high price?Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - August 9, 2016 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Teva Announces Launch of Generic Gleevec(R) Tablets in the United States
JERUSALEM--(Healthcare Sales & Marketing Network)--Teva Pharmaceutical Industries Ltd., (NYSE and TASE:TEVA) today announced the launch of the generic equivalent to Gleevec®1(imatinib mesylate) tablets,100 mg and 400 mg, in the United States for multip... Biopharmaceuticals, Generics, Oncology, Product Launch Teva Pharmaceutical, Gleevec, imatinib (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - August 5, 2016 Category: Pharmaceuticals Source Type: news
Long-term dasatinib supported in CML
Dasatinib has durable efficacy and manageable toxicity in the long-term treatment of patients with chronic-phase chronic myeloid leukaemia that is resistant or intolerant to imatinib, shows final analysis of the CA180-034 trial. (Source: MedWire News)
Source: MedWire News - July 22, 2016 Category: Consumer Health News Tags: Chronic myeloid leukaemia Source Type: news
A Comprehensive And Fair Solution To The Price Of Medicines
After a long dry spell, the pharmaceutical research industry has brought to market a spate of innovative treatments that can extend life and often have fewer side effects than older treatments. But these medicines are not affordable to most of the people who need them. Recent treatments for hepatitis C and cancer - both widespread conditions globally - can cost from $50,000 annually to well over $150,000.
At the other end of the spectrum, the generic pharmaceutical industry is losing interest in manufacturing older, off-patent medicines because the market price has been slashed to a level that it no longer provides an ...
Source: Science - The Huffington Post - June 28, 2016 Category: Science Source Type: news
UC regents appoint Dr. Owen Witte University Professor
Dr. Owen Witte, renowned scientist and esteemed member of UCLA’s faculty, has been appointed a University Professor by the University of California Board of Regents. This appointment is reserved for scholars of the highest international distinction, who are respected as teachers of exceptional ability and whose contributions elevate the entire UC system.
The University Professor title was established by the regents so that the entire UC system can benefit from the talents of outstanding faculty. Witte joins the ranks of just 40 UC faculty, including several Nobel laureates, who have received this honor since 1960.
“Dr....
Source: UCLA Newsroom: Health Sciences - June 10, 2016 Category: Universities & Medical Training Source Type: news
Colombia to set new price for Novartis cancer drug: minister
BOGOTA (Reuters) - Colombia will set a new price for the Novartis cancer drug imatinib in a bid to cut healthcare costs after price negotiations with the Swiss company broke down, the health minister said on Thursday. (Source: Reuters: Health)
Source: Reuters: Health - June 9, 2016 Category: Consumer Health News Tags: healthNews Source Type: news
Essential medicine for leukemia, stomach cancer to become cheaper in India
The regulatory body has cut by nearly 30% the price of Imatinib, used to treat cancers and blood diseases, including different types of leukemia and stomach cancers. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - June 7, 2016 Category: Pharmaceuticals Source Type: news
Cancer Patients with ACA Policies Swiftly Reach Out-of-Pocket Caps
Contact: Sarah Avery Phone: 919-660-1306 Email: sarah.avery@duke.edu https://www.dukehealth.org
ASCO Abstract #6504
FOR IMMEDIATE RELEASE on Saturday, June 4, 2016
DURHAM, N.C. – A hypothetical leukemia patient buying the life-extending drug therapy for his condition would reach his annual out-of-pocket maximum in a month on most of the bronze policies and half of the silver policies offered through the Affordable Care Act marketplace.
The findings, reported by researchers at the Duke Cancer Institute at the American Society of Clinical Oncology meeting in Chicago (Abstract #6504), found that cancer patients buying ...
Source: DukeHealth.org: Duke Health Features - June 4, 2016 Category: Pediatrics Tags: Duke Medicine Source Type: news
Fy17 forecast: Sun Pharma expects 8-10 per cent sales growth
The company, which made windfall gains in the fourth quarter from sales of cancer drug imatinib in the US, said it will invest up to 9% of sales in research. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - May 31, 2016 Category: Pharmaceuticals Source Type: news
Drug Targeting Blood-Brain Barrier 'Hopeful' in Stroke Drug Targeting Blood-Brain Barrier 'Hopeful' in Stroke
Imatinib, a drug that is already available for the treatment of cancer, showed positive results in an initial randomized study in ischemic stroke. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 26, 2016 Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news
Colombia Threatens to Override Novartis's Patent on Gleevec
Colombia’s government will override Novartis’s patent on a cancer medication by the end of May and open it up to generic manufacturers unless the Swiss pharmaceutical giant accepts a price cut. (Source: WSJ.com: Health)
Source: WSJ.com: Health - May 20, 2016 Category: Pharmaceuticals Tags: PAID Source Type: news
